Phathom Pharmaceuticals (PHAT) PT Raised to $29 at Cantor Fitzgerald

Guggenheim on Phathom Pharmaceuticals (PHAT): 'Our NPV analysis suggests fair value in the $12-14 range'

Guggenheim analyst Yatin Suneja reiterated a Buy rating and $12.00 price target on Phathom Pharmaceuticals (NASDAQ: PHAT).

The analyst comments "Recall that in Dec 2024, PHAT submitted a Citizen Petition (CP) to the FDA to formally request correction to the Orange Book listings for 10 mg... More

Stifel Reiterates Buy Rating on Phathom (PHAT), PT $28, 'We leave our model unchanged, as our view reflected full 10-year exclusivity'

Stifel analyst Annabel Samimy reiterated a Buy rating and $28.00 price target on Phathom Pharmaceuticals (NASDAQ: PHAT).

The analyst comments "Voquezna Granted CP and Officially Gains 10-Year Exclusivity, Extending to 2032: Recall, last December PHAT filed a citizens petition/ CP to proactively nudge the FDA to update the Orange... More

Phathom Pharmaceuticals (PHAT) Announces Positive FDA Decision to Recognize 10 Years of Regulatory Exclusivity for VOQUEZNA Tablets through May 3, 2032

Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT) today announced that the U.S. Food and Drug Administration (FDA) has approved Phathoms Citizen Petition filed on December 11, 2024 and communicated the Agencys intention to correct the Orange Book to recognize the proper 10 years of New Chemical Entity exclusivity... More

Phathom Pharmaceuticals shares soar on FDA exclusivity grant

Investing.com -- Shares of Phathom Pharmaceuticals Inc. (NASDAQ: PHAT) soared 128% after the FDA granted the companys petition for exclusivity in the Orange Book listing for its drug Voquezna (vonoprazan fumarate). The decision by the Food and Drug Administration to extend the exclusivity period to a full 10 years for Voquezna, under the umbrella of the... More

Phathom Pharmaceuticals Inc. (PHAT) Halted on Circuit Breaker, Up 59%

Phathom Pharmaceuticals Inc. (NASDAQ: PHAT) Halted on Circuit Breaker, Up 59%

Phathom Pharmaceuticals (PHAT) Petition Granted by FDA

(Updated - June 6, 2025 11:51 AM EDT)

Phathom Pharmaceuticals Inc. (NASDAQ: PHAT) Surges 59% After a Letter from the FDA.

From the FDA:

This letter responds to your citizen petition submitted on behalf of Phathom Pharmaceuticals, Inc. (Phathom), and received on December 11, 2024 (Petition). In the Petition, you request that the Food and Drug Administration (FDA or Agency) correct the publication,... More